In an effort to enhance medical solutions for patients suffering from Benign Prostatic Hyperplasia (BPH), Sanfine International Hospital is excited to introduce two innovative "ultra-minimally invasive" technologies: The Urolift System for Prostatic Urethral Lift (PUL) and Boston Scientific’s Rezūm Water Vapor Therapy.
Entering the Era of "Ultra-Minimally Invasive Treatment"
With procedures requiring just minutes to perform, these advanced technologies offer patients a dramatically less traumatic, safer, and more effective treatment experience. Notably, these methods also preserve male function, marking a significant step forward in patient care.
Empowering Patient Health Through Medical Technology
It is a well-known fact that more than half of all men over the age of 50 globally suffer from BPH, and this figure climbs to 90% in men over 80. As China's aging population increases, the prevalence of BPH is expected to rise, profoundly affecting the quality of life for many elderly men.
While traditional surgical options and laser treatments for BPH exist, they often require 1-2 hours and involve risks linked with general anesthesia and postoperative complications. These risks dissuade many patients, who instead turn to conservative pharmacotherapy, which can have limited efficacy and potential side effects. Herein lies the revolutionary advantage of ultra-minimally invasive treatments like Rezūm and Urolift.
Spotlight on Rezūm Water Vapor Ablation Technology
The Rezūm technology uses a unique approach to treat BPH. It involves injecting sterile water vapor at a temperature of 103°C directly into the adenomatous tissue of the prostate. The steam disperses rapidly through the target tissue, causing immediate cell death within the enlarged prostate tissue, which is then naturally absorbed by the body. This results in the prostate shrinking and alleviates symptoms like difficulty urinating and nocturia.
The key advantage of Rezūm is its ability to target and treat the prostate tissue without damaging surrounding structures, thereby preserving erectile and ejaculatory functions. This makes it an ideal option for elderly patients who are sensitive to surgical risks and younger patients wishing to maintain sexual function.
Clinical Evidence and Utilization
A global multicenter clinical study has demonstrated that five years post-Rezūm treatment, patients report significant improvements in Lower Urinary Tract Symptoms (LUTS), quality of life (QOL), and urinary flow. Importantly, the rate of retreatment remains low at just 4.4% over five years.
Day Surgery Convenience
Rezūm is recognized globally as the first steam treatment device for BPH. Since its introduction, over 200,000 Rezūm procedures have been conducted worldwide. Recommended by the American Urological Association (AUA) in their 2019 guidelines for prostates up to 80cc, the procedure is notable for its efficiency and convenience. It requires only local anesthesia and can be performed in an outpatient setting, with most patients able to go home the same day. The entire procedure typically takes just 5-8 minutes.
Who Is a Candidate for Rezūm Steam Treatment?
Candidates for Rezūm steam treatment include:
- Patients with a prostate volume of less than 80cc.
- Patients experiencing significant median lobe growth affecting quality of life.
- Patients looking to maintain sexual function while seeking effective treatment for BPH.
For more information, or to schedule a consultation, visit Sanfine International Hospital's official website or contact our patient services team. Empowering patient health through innovative medical technology, Sanfine International Hospital continues to lead in providing state-of-the-art care.
